Divalproex ER vs. Risperidone for Bipolar Disorder With Comorbid Substance Use Disorder
Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
The primary objective is to evaluate the safety and efficacy of divalproex extended release
(ER) compared to risperidone in the treatment of bipolar disorder with comorbid substance use
disorder
Phase:
Phase 4
Details
Lead Sponsor:
Tuscaloosa Research & Education Advancement Corporation